Cargando…

Nanotechnology for virus treatment

The continued emergence of novel viruses poses a significant threat to global health. Uncontrolled outbreaks can result in pandemics that have the potential to overburden our healthcare and economic systems. While vaccination is a conventional modality that can be employed to promote herd immunity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiarong, Krishnan, Nishta, Jiang, Yao, Fang, Ronnie H., Zhang, Liangfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836394/
https://www.ncbi.nlm.nih.gov/pubmed/33519948
http://dx.doi.org/10.1016/j.nantod.2020.101031
_version_ 1783642739701710848
author Zhou, Jiarong
Krishnan, Nishta
Jiang, Yao
Fang, Ronnie H.
Zhang, Liangfang
author_facet Zhou, Jiarong
Krishnan, Nishta
Jiang, Yao
Fang, Ronnie H.
Zhang, Liangfang
author_sort Zhou, Jiarong
collection PubMed
description The continued emergence of novel viruses poses a significant threat to global health. Uncontrolled outbreaks can result in pandemics that have the potential to overburden our healthcare and economic systems. While vaccination is a conventional modality that can be employed to promote herd immunity, antiviral vaccines can only be applied prophylactically and do little to help patients who have already contracted viral infections. During the early stages of a disease outbreak when vaccines are unavailable, therapeutic antiviral drugs can be used as a stopgap solution. However, these treatments do not always work against emerging viral strains and can be accompanied by adverse effects that sometimes outweigh the benefits. Nanotechnology has the potential to overcome many of the challenges facing current antiviral therapies. For example, nanodelivery vehicles can be employed to drastically improve the pharmacokinetic profile of antiviral drugs while reducing their systemic toxicity. Other unique nanomaterials can be leveraged for their virucidal or virus-neutralizing properties. In this review, we discuss recent developments in antiviral nanotherapeutics and provide a perspective on the application of nanotechnology to the SARS-CoV-2 outbreak and future virus pandemics.
format Online
Article
Text
id pubmed-7836394
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78363942021-01-26 Nanotechnology for virus treatment Zhou, Jiarong Krishnan, Nishta Jiang, Yao Fang, Ronnie H. Zhang, Liangfang Nano Today Article The continued emergence of novel viruses poses a significant threat to global health. Uncontrolled outbreaks can result in pandemics that have the potential to overburden our healthcare and economic systems. While vaccination is a conventional modality that can be employed to promote herd immunity, antiviral vaccines can only be applied prophylactically and do little to help patients who have already contracted viral infections. During the early stages of a disease outbreak when vaccines are unavailable, therapeutic antiviral drugs can be used as a stopgap solution. However, these treatments do not always work against emerging viral strains and can be accompanied by adverse effects that sometimes outweigh the benefits. Nanotechnology has the potential to overcome many of the challenges facing current antiviral therapies. For example, nanodelivery vehicles can be employed to drastically improve the pharmacokinetic profile of antiviral drugs while reducing their systemic toxicity. Other unique nanomaterials can be leveraged for their virucidal or virus-neutralizing properties. In this review, we discuss recent developments in antiviral nanotherapeutics and provide a perspective on the application of nanotechnology to the SARS-CoV-2 outbreak and future virus pandemics. Elsevier Ltd. 2021-02 2020-12-01 /pmc/articles/PMC7836394/ /pubmed/33519948 http://dx.doi.org/10.1016/j.nantod.2020.101031 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zhou, Jiarong
Krishnan, Nishta
Jiang, Yao
Fang, Ronnie H.
Zhang, Liangfang
Nanotechnology for virus treatment
title Nanotechnology for virus treatment
title_full Nanotechnology for virus treatment
title_fullStr Nanotechnology for virus treatment
title_full_unstemmed Nanotechnology for virus treatment
title_short Nanotechnology for virus treatment
title_sort nanotechnology for virus treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836394/
https://www.ncbi.nlm.nih.gov/pubmed/33519948
http://dx.doi.org/10.1016/j.nantod.2020.101031
work_keys_str_mv AT zhoujiarong nanotechnologyforvirustreatment
AT krishnannishta nanotechnologyforvirustreatment
AT jiangyao nanotechnologyforvirustreatment
AT fangronnieh nanotechnologyforvirustreatment
AT zhangliangfang nanotechnologyforvirustreatment